Zentalis Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:ZNTL)

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) was the recipient of some unusual options trading activity on Monday. Stock traders bought 3,891 call options on the company. This represents an increase of 5,886% compared to the average daily volume of 65 call options.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of ZNTL. Quest Partners LLC acquired a new stake in shares of Zentalis Pharmaceuticals during the fourth quarter valued at about $38,000. Anfield Capital Management LLC acquired a new position in shares of Zentalis Pharmaceuticals in the second quarter valued at approximately $40,000. SG Americas Securities LLC purchased a new position in Zentalis Pharmaceuticals in the second quarter worth approximately $58,000. Algert Global LLC purchased a new position in Zentalis Pharmaceuticals in the second quarter worth approximately $78,000. Finally, American Century Companies Inc. purchased a new position in Zentalis Pharmaceuticals in the second quarter worth approximately $95,000.

Zentalis Pharmaceuticals Price Performance

Zentalis Pharmaceuticals stock opened at $4.10 on Wednesday. The stock has a market cap of $291.21 million, a price-to-earnings ratio of -1.23 and a beta of 1.70. Zentalis Pharmaceuticals has a 1 year low of $2.83 and a 1 year high of $23.52. The firm has a 50-day moving average of $3.54 and a two-hundred day moving average of $8.62.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings data on Friday, August 9th. The company reported ($1.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.40). During the same period in the previous year, the business posted ($1.85) EPS. Research analysts expect that Zentalis Pharmaceuticals will post -2.95 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently commented on ZNTL shares. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Zentalis Pharmaceuticals in a research report on Monday, August 12th. Jefferies Financial Group reissued a “hold” rating and issued a $6.00 price target (down from $42.00) on shares of Zentalis Pharmaceuticals in a research note on Tuesday, June 18th. Wells Fargo & Company downgraded shares of Zentalis Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lowered their price objective for the company from $29.00 to $9.00 in a research note on Tuesday, June 18th. Stifel Nicolaus lowered their price objective on shares of Zentalis Pharmaceuticals from $32.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, June 18th. Finally, UBS Group cut shares of Zentalis Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the company from $28.00 to $5.00 in a research report on Thursday, June 20th. Seven research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $10.78.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.